Porter et al. ( 1 ) recently described their evaluation of the association between survival and p27 Kip1 and cyclin E immunohistochemical staining on tissue microarrays from 2123 breast cancer patients treated with doxorubicin and cyclophosphamide. Although p27
Kip1 was statistically significantly associated with survival, cyclin E was not found to be associated with survival.
This observation is in contrast to previous results from Keyomarsi et al. ( 2 ) , in which cyclin E, as assessed by western blot analysis, was the most prominent independent prognostic factor associated with breast cancer outcome. However, western blot analysis is a time-consuming technique that requires a large amount of tumor tissue and so is not practical for routine risk assessment of breast cancer patients. This technique does, however, detect the low -molecular-weight form of cyclin E, which is not (specifi cally) recognized by most cyclin E antibodies that are used in immunohistochemistry. Overall, the results for the association between cyclin E and breast cancer outcome have been diverse. Many authors, including Porter et al. ( 1 ) , have attributed these disparate results to various forms of cyclin E that might not have been measured with the techniques used in these studies.
We agree that differences in analyses (i.e., reverse transcription -polymerase chain reaction [RT -PCR], immunohistochemistry, or western blot) could have a major impact on the results. However, we have found previously ( 3 ) that the association between cyclin E and disease outcome was restricted to patients who were treated with tamoxifen in the adjuvant setting. It has been shown ( 4 ) that overexpression of the low -molecular-weight form of cyclin E by breast cancer cells is associated with resistance to antiestrogens in vitro. Furthermore, this association was recently confi rmed in additional patient cohorts ( 4 , 5 ) . If cyclin E is indeed specifi cally associated with endocrine therapy resistance, then this explanation is also valid for the lack of an association between cyclin E and survival in the study of Porter et al. ( 1 ) because all patients in that cohort received only chemotherapy.
A study of cyclin E expression, as assessed by RT -PCR or immunohistochemistry, preferably directed to the lowmolecular-weight form of cyclin E, in a cohort of patients treated with endocrine therapy would resolve the issue of whether cyclin E is associated with breast cancer disease progression. 
